US Stock MarketDetailed Quotes
FGEN FibroGen
- 0.313
- +0.002+0.77%
Close Nov 7 16:00 ET
- 0.326
- +0.013+4.22%
Post 17:15 ET
31.41MMarket Cap-184P/E (TTM)
0.325High0.302Low994.03KVolume0.310Open0.310Pre Close314.49KTurnover1.10%Turnover RatioLossP/E (Static)100.40MShares2.93052wk High-0.14P/B28.32MFloat Cap0.29052wk Low--Dividend TTM90.52MShs Float68.550Historical High--Div YieldTTM7.54%Amplitude0.290Historical Low0.316Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
FibroGen Stock Forum
hope you can perform again 💪💪💪
FibroGen Inc - Study Did Not Meet Primary Endpoint
FibroGen, Inc. (NASDAQ:FGEN) recently announced a milestone in its oncology pipeline. The U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for FG-3165, a novel galectin-9 (Gal9) targeted monoc...
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
FibroGen (NASDAQ: FGEN) announced FDA clearance for its Investigational New Drug (IND) application for FG-3165, a monoclonal antibody targeting galectin-9 (Gal9) for treating solid tumors. FG-3165 has shown anti-tumor activity and improved survival in preclinical models and exhibited excellent tol...
FibroGen Announces Clinical Trial Supply Agreement With Regeneron Pharmaceuticals to Evaluate Fibrogen’s Immuno-Oncology Assets, FG-3165 (Anti-Galectin 9) and FG-3175 (Anti-Ccr8), in Combination With Libtayo® in Upcoming Clinical Trials
No comment yet